טוען...
Comparison between coagulation factor VIII quantified with one‐stage activity assay and with mass spectrometry in haemophilia A patients: Proof of principle
INTRODUCTION: Haemophilia A is a hereditary bleeding disorder caused by a factor VIII (FVIII) deficiency. As biomarker, FVIII activity is used to classify disease severity and to monitor treatment. The one‐stage clotting assay (OSA) is performed to measure FVIII activity, but OSA's limitations...
שמור ב:
| הוצא לאור ב: | Int J Lab Hematol |
|---|---|
| Main Authors: | , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
John Wiley and Sons Inc.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7754357/ https://ncbi.nlm.nih.gov/pubmed/32633067 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijlh.13283 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|